FLIP-α (CT) Blocking Peptide

FLIP-α (CT) Blocking Peptide

Product No.: F146

[product_table name="All Top" skus="F146"]

- -
- -
Target
FLICE Inhibitory Protein
Product Type
Blocking Peptide
Alternate Names
Casper, I-FLICE, FLAME-1, CASH, CLARP

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
This peptide sequence is located at amino acids 447 to 464 of Human FLIP-α protein.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Amino Acid Sequence
18 amino acids near the carboxy terminus of human FLIP.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Background
FLICE Inhibitory Protein peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

References & Citations

1. Schievella AR, Chen JH, Graham JR, Lin LL. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem 1997;272:12069-12075 2. Chow VT, Lee SS. DENN, a novel human gene differentially expressed in normal and neoplastic cells. DNA Seq 1996;6:263-273 3. Zhang Y, Zhou L, Miller CA. A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system. Proc Natl Acad Sci U S A 1998;95:2586-2591 4. Brown TL and Howe PH. MADD is highly homologous to a Rab3 guanine-nucleotide exchange protein (Rab3-GEP). Curr Biol 1998;8:R191
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.